文献速递消化系统肿瘤

循环GPNMB多模态模型整合肿瘤免疫交互预测食管癌免疫治疗反应

A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

新辅助免疫治疗改善食管鳞癌(ESCC)预后,但约70%患者无效。研究通过血浆蛋白质组学发现非应答者循环可溶性GPNMB(sGPNMB)升高,机制上肿瘤来源sGPNMB经SDC4-CD148轴抑制CD8+ T细胞受体信号并诱导耗竭。整合血浆GPNMB、CAF-Epi生态位检测及临床病理特征的多模态模型在回顾队列与前瞻试验中稳健预测免疫治疗反应与生存。

要点

  • 血浆sGPNMB是非应答者最升高的循环蛋白,可预测PD-1阻断反应。
  • 肿瘤sGPNMB经SDC4-CD148轴抑制CD8+ T细胞功能,其分泌为免疫抑制所必需。
  • CAF-Epi生态位促进SOX2上调转录激活GPNMB,抑制GPNMB与PD-1阻断协同。

核心结论

  • 肿瘤来源可溶性GPNMB由CAF-Epi生态位内SOX2转录激活,驱动CD8+ T细胞耗竭及PD-1阻断耐药。
  • 整合循环GPNMB、CAF-Epi生态位特征及临床病理因素的多模态模型可稳健预测ESCC免疫治疗反应与生存。

研究设计与样本

  • 研究进行血浆蛋白质组学分析,鉴定非应答者中升高的循环蛋白。
  • 机制研究涉及肿瘤细胞来源sGPNMB通过SDC4-CD148轴诱导CD8+ T细胞功能耗竭。
  • 在人源化患者来源异种移植(PDX)模型中验证循环GPNMB预测PD-1阻断反应及GPNMB抑制的协同作用。
  • 在回顾性队列和一项前瞻性临床试验中构建并验证多模态预测模型。

主要发现

  • 非应答者血浆中可溶性GPNMB(sGPNMB)是最升高的循环蛋白。
  • 肿瘤细胞来源sGPNMB通过SDC4-CD148轴抑制CD8+ T细胞受体信号,诱导功能性耗竭,且其分泌为免疫抑制活性所必需。
  • 癌症相关成纤维细胞-上皮(CAF-Epi)生态位促进肿瘤细胞SOX2上调,转录激活GPNMB表达。
  • 人源化PDX模型中循环GPNMB水平预测PD-1阻断反应,抑制GPNMB与治疗协同。
  • 多模态模型整合血浆GPNMB水平、CAF-Epi生态位检测及临床病理特征,对免疫治疗反应和生存显示稳健预测准确性。

临床怎么用

  • 基于血浆GPNMB水平、CAF-Epi生态位检测及临床病理特征的多模态模型可用于筛选可能从新辅助免疫治疗获益的ESCC患者。
  • 循环GPNMB水平可预测PD-1阻断反应,GPNMB抑制与PD-1阻断联用具协同潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Neoadjuvant immunotherapy improves outcomes in esophageal squamous cell carcinoma (ESCC), yet ∼70% of patients fail to respond. Pretreatment biopsies and plasma provide critical opportunities for biomarker discovery. In this study, we performed plasma proteomic profiling and identified soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) as the most elevated circulating protein in nonresponders. Mechanistically, tumor cell-derived sGPNMB suppressed CD8+ T-cell receptor signaling via the SDC4-CD148 axis to induce functional exhaustion, with secretion being required for its immunosuppressive activity. Cancer-associated fibroblast-epithelial (CAF-Epi) niches promoted SOX2 upregulation in tumor cells, transcriptionally activating GPNMB expression. In humanized patient-derived xenograft models, circulating GPNMB levels predicted response to PD-1 blockade, and GPNMB inhibition synergized with therapy. Across retrospective cohorts and a prospective clinical trial, a multimodal model combining plasma GPNMB levels, CAF-Epi niche detection, and clinical-pathologic features achieved robust predictive accuracy for immunotherapy response and survival. These findings establish a spatial-circulating biomarker framework for precision ESCC immunotherapy. SIGNIFICANCE: Tumor-derived soluble GPNMB, transcriptionally activated by SOX2 within CAF-Epi niches, drives CD8+ T-cell exhaustion and resistance to PD-1 blockade in ESCC. Integrating circulating GPNMB levels with CAF-Epi niche features and clinical-pathologic factors, we develop and validate a clinically scalable multimodal model for predicting immunotherapy response.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhu L, Wang X, Cheng G, et al. A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. Cancer Discov. 2026. PMID: 41747244. doi:10.1158/2159-8290.CD-25-1907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。